A case of metastatic urachal adenocarcinoma treated with several

Authors

  • Christine Elser Medical Oncologist, Assistant Professor, Department of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, ON
  • Joan Sweet Pathologist, Department of Pathology, University Health Network, Toronto, ON
  • Sendhil K. Cheran Radiologist, Department of Radiology, University Health Network, Toronto, ON
  • Masoom A. Haider Radiologist, Department of Radiology, University Health Network, Toronto, ON;
  • Michael Jewett Urologist, Department of Urology, Princess Margaret Hospital, Toronto, ON
  • Srikala S. Sridhar Medical Oncologist, Assistant Professor, Department of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, ON

DOI:

https://doi.org/10.5489/cuaj.336

Abstract

Urachal cancer is a rare form of bladder cancer that arises from
the urachus, a vestigial musculofibrous band that extends from the
dome of the bladder to the umbilicus. Urachal cancer often presents
at an advanced stage and has a dismal prognosis. We present
a case of a young woman with urachal cancer that recurred rapidly
post-partial cystectomy. The patient was treated with up to 6 different chemotherapy regimens, including an oral antiangiogenic drug as part of a clinical trial. Our case illustrates the aggressive nature of this disease, the difficulty in accessing drugs for the treatment of rare cancers and the lack of late stage clinical trials to help guide therapeutic decisions.

Downloads

Download data is not yet available.

Author Biographies

Christine Elser, Medical Oncologist, Assistant Professor, Department of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, ON

Joan Sweet, Pathologist, Department of Pathology, University Health Network, Toronto, ON

Sendhil K. Cheran, Radiologist, Department of Radiology, University Health Network, Toronto, ON

Masoom A. Haider, Radiologist, Department of Radiology, University Health Network, Toronto, ON;

Michael Jewett, Urologist, Department of Urology, Princess Margaret Hospital, Toronto, ON

Srikala S. Sridhar, Medical Oncologist, Assistant Professor, Department of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, ON

Downloads

Published

2013-02-24

How to Cite

Elser, C., Sweet, J., Cheran, S. K., Haider, M. A., Jewett, M., & Sridhar, S. S. (2013). A case of metastatic urachal adenocarcinoma treated with several. Canadian Urological Association Journal, 6(1), E27-E31. https://doi.org/10.5489/cuaj.336

Issue

Vol. 6 No. 1 (2012): CUAJ February

Section

Case Report

License

You, the Author(s), assign your copyright in and to the Article to the Canadian Urological Association. This means that you may not, without the prior written permission of the CUA:

  • Post the Article on any Web site
  • Translate or authorize a translation of the Article
  • Copy or otherwise reproduce the Article, in any format, beyond what is permitted under Canadian copyright law, or authorize others to do so
  • Copy or otherwise reproduce portions of the Article, including tables and figures, beyond what is permitted under Canadian copyright law, or authorize others to do so.

The CUA encourages use for non-commercial educational purposes and will not unreasonably deny any such permission request.

You retain your moral rights in and to the Article. This means that the CUA may not assert its copyright in such a way that would negatively reflect on your reputation or your right to be associated with the Article.

The CUA also requires you to warrant the following:

  • That you are the Author(s) and sole owner(s), that the Article is original and unpublished and that you have not previously assigned copyright or granted a licence to any other third party;
  • That all individuals who have made a substantive contribution to the article are acknowledged;
  • That the Article does not infringe any proprietary right of any third party and that you have received the permissions necessary to include the work of others in the Article; and
  • That the Article does not libel or violate the privacy rights of any third party.